Sur­rozen paus­es PhI clin­i­cal tri­al in ul­cer­a­tive col­i­tis due to ad­verse events in liv­er

Just over a month af­ter Wnt play­er Sur­rozen hand­ed off its reti­nal dis­ease can­di­date to Boehringer In­gel­heim, the San Fran­cis­co biotech is re­port­ing clin­i­cal is­sues …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER